Thumb Arthritis Market Analysis

Growing aging population is driving the market growth

The majority of people with thumb arthritis are over 40, and the world's population is ageing significantly. Arthritis may develop in the thumb joint as people age due to wear and tear over time. The market for choices for diagnosis, treatment, and management of thumb arthritis is directly impacted by this rise in prevalence. Additionally, ageing is linked to the body's normal degenerative processes, which include alterations to the joints. The cartilage in the thumb joint may deteriorate with time, resulting in the onset of thumb arthritis.

Factors including prior injuries, a hereditary propensity, or repetitive use of the thumb joint might worsen these degenerative changes. Treatments for thumb arthritis are now more widely available to a bigger population due to rising healthcare costs and the availability of medical insurance. The market CAGR for thumb arthritis has risen as a result of this.

The market for thumb arthritis is significantly influenced by changes in lifestyle. Many people today lead sedentary lifestyles with little to no physical activity. Weak muscles, inadequate joint support, and increased stress on the thumb joint can all be results of inactivity. The onset or course of thumb arthritis might be influenced by a lack of consistent physical activity. Additionally, obesity is becoming more and more commonplace in the world. The thumb joint is particularly stressed by excess body weight, which accelerates cartilage deterioration and wear.

Inflammation and joint damage can be brought on by poor dietary decisions, such as a high intake of processed foods, saturated fats, and sugary beverages. Some meals, such as those rich in purines, which are present in red meat, seafood, and alcohol, can cause inflammation and exacerbate the signs and symptoms of thumb arthritis. Additionally, thumb arthritis can be accelerated by acute injuries or chronic misuse of the thumb joint. Sports, hard labour, and hobbies that require repetitive thumb motions can all lead to joint irritation and damage over time. Thus, driving the thumb arthritis market revenue.

The Global Thumb Arthritis Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.47 USD Billion in 2024, it is anticipated to reach 1.15 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.48% from 2025 to 2035. This growth trajectory indicates a robust demand for treatment options and innovations in the field of thumb arthritis. Stakeholders in the industry must remain vigilant in adapting to changing market dynamics and consumer needs to capitalize on this promising growth opportunity.

The aging population worldwide is a critical driver of the Global Thumb Arthritis Market Industry. As individuals age, the likelihood of developing osteoarthritis, including thumb arthritis, increases. This demographic shift is particularly pronounced in developed countries, where healthcare systems are increasingly focused on managing chronic conditions associated with aging. The growing geriatric population is expected to lead to a higher incidence of thumb arthritis, thereby driving demand for treatment options. With the market projected to reach 1.15 USD Billion by 2035, addressing the needs of this demographic will be essential for stakeholders in the industry.

The Global Thumb Arthritis Market Industry benefits from increasing awareness and education regarding thumb arthritis. Public health campaigns and educational initiatives are helping to inform individuals about the symptoms, risk factors, and treatment options available. This heightened awareness encourages early diagnosis and intervention, which can significantly improve patient outcomes. As more people become informed about thumb arthritis, the demand for medical consultations and therapeutic interventions is likely to rise. Consequently, this trend may contribute to the market's growth, as healthcare systems adapt to meet the needs of a more informed patient population.

Innovations in the treatment landscape for thumb arthritis are significantly influencing the Global Thumb Arthritis Market Industry. The development of minimally invasive surgical techniques, biologics, and advanced pharmacological therapies is enhancing patient outcomes. These advancements not only improve the quality of life for patients but also expand the range of available treatment options. As healthcare providers adopt these new technologies, the market is likely to see increased investment and growth. The anticipated compound annual growth rate (CAGR) of 8.48% from 2025 to 2035 underscores the potential for continued expansion driven by these advancements.

The Global Thumb Arthritis Market Industry is experiencing growth due to the rising prevalence of thumb arthritis among various demographics. Factors such as aging populations and increased participation in activities that strain the thumb joint contribute to this trend. In 2024, the market is valued at approximately 0.47 USD Billion, reflecting the growing need for effective treatment options. As awareness of thumb arthritis increases, more individuals seek medical attention, thereby driving demand for innovative therapies and products. This trend is expected to continue, with projections indicating a market value of 1.15 USD Billion by 2035, suggesting a robust growth trajectory.

The Global Thumb Arthritis Market Industry is also influenced by the rising participation in sports and physical activities, which can lead to thumb injuries and subsequent arthritis. As more individuals engage in recreational and competitive sports, the incidence of thumb-related injuries may rise, contributing to the development of arthritis. This trend is particularly relevant among younger populations, who may experience long-term consequences from acute injuries. The market's growth is likely to be fueled by the need for preventive measures and treatments for thumb arthritis, as awareness of the connection between sports participation and joint health continues to grow.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the thumb arthritis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, thumb arthritis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  thumb arthritis industry to benefit clients and increase the market sector. In recent years, the thumb arthritis industry has offered some of the most significant advantages to market. Major players in the thumb arthritis market attempting to increase market demand by investing in research and development operations include BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others.

Amgen Inc. is a biotechnology firm that finds, develops, produces, and sells cutting-edge human pharmaceuticals to treat patients with severe diseases. It creates innovative treatments for conditions related to the cardiovascular system, inflammation, oncology/hematology, bone health, neurological problems, and nephrology. The business creates products employing cutting-edge human genetics to comprehend the basics of human biology and analyze the challenges of disease. In the US, Amgen mostly sells its goods to wholesale distributors of pharmaceuticals. Additionally, it uses partnerships with other businesses and direct-to-consumer channels to sell specific products to customers.

AbbVie Inc. is a specialized biopharmaceutical firm that finds, develops, produces, and sells medications for the management of chronic and difficult-to-treat disorders. Its medications are approved for the treatment of cancer, neurological disorders, rheumatoid arthritis, endometriosis pain, pediatric Crohn's disease, metabolic and rheumatological diseases, skin issues, and other significant medical ailments. Additionally, Crohn's disease, Parkinson's disease, viral illnesses, wet AMD, various malignancies, neurological disorders, aesthetic conditions, and other autoimmune diseases are among the pipeline diseases that AbbVie is pushing.